MICHELLE ELLENBURG: Open Payments
NPI 1316327661 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$529 in 29 payments from 15 companies in 2025. Trend: 2023 $333 · 2024 $274 · 2025 $529
Food & beverage: $529
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $87 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Amgen Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Abbott Laboratories | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $24 |
Products named: GEMTESA, OTEZLA, REXULTI, CREON, FREESTYLE LIBRE 3, Veozah, ZENPEP, VRAYLAR.
Industry payments across OK — which companies pay providers there.
